Optimising Treatment of HF

Views:
18435
Likes:
7
Share:

Part 3 of 5

< Prev Next >

PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

Javed Butler

Download Slides

Overview

Following recent changes to guidelines in light of the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes, this programme brings together a leading faculty to best inform of the latest clinical evidence and real-world application for optimising treatment strategies in heart failure.

Prof Martin Cowie (Imperial College London, UK), moderates the proceedings, that comprises a number of insightful presentations and a panel discussion, with contributions from Prof Giuseppe Rosano (St George's Hospitals NHS Trust, London, UK), Dr Javed Butler (University of Mississippi, US), and Dr Shelley Zieroth (University of Manitoba, Canada).

Intended for healthcare professionals only. This IME programme is supported by an unrestricted educational grant from AstraZeneca, who has had no involvement in its organisation. Views and opinions expressed in the programme belong to the authors (faculty and delegates) and not necessarily to that of AstraZeneca.

Learning objectives

Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases

Audience

Heart Failure Specialists
General Cardiologists
Nurses
Allied Health Professionals

More from this programme

Part 1

PART 1 – Introduction – Optimising Treatment of HF

Prof Martin Cowie introduces the topic, and reviews the learning objectives of the programme.

1 session
PART 1 – Introduction – Optimising Treatment of HF	Watch now

Part 2

PART 2 – A Review of Recent SGLT2 Inhibitor Data

Prof Giuseppe Rosano reviews recent SGLT2 trial data, including DAPA – HF, and Emperor Reduced.

1 session
PART 2 – A Review of Recent SGLT2 Inhibitor Data	Watch now

Part 3

PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

Dr Javed Butler presents a case, and considers available treatment strategies, and the optimal approach for HFrEF medications.

1 session
PART 3 – New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?	Watch now

Part 4

PART 4 – Existing HF-REF: Augmenting the SOC

Dr Shelley Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.

1 session
PART 4 – Existing HF-REF: Augmenting the SOC	Watch now

Part 5

PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?

Prof Cowie moderates a discussion with the faculty.

1 session
PART 5 – How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?	Watch now

Faculty Biographies

Javed Butler

Professor of Medicine

Dr Javed Butler is President, Baylor Scott and White Research Institute, Dallas, TX and Professor of Medicine, University of Mississippi, Jackson, MS, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He has authored more than 900 peer-reviewed publications.

View full profile